Literature DB >> 1703335

Lymphoproliferative disorders arising under immunosuppression with FK 506: initial observations in a large transplant population.

M A Nalesnik1, A J Demetris, J J Fung, T E Starzl.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1703335      PMCID： PMC2964003     

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  7 in total

1.  Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers.

Authors:  R Y Calne; K Rolles; D J White; S Thiru; D B Evans; P McMaster; D C Dunn; G N Craddock; R G Henderson; S Aziz; P Lewis
Journal:  Lancet       Date:  1979-11-17       Impact factor: 79.321

2.  A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin.

Authors:  J J Siekierka; S H Hung; M Poe; C S Lin; N H Sigal
Journal:  Nature       Date:  1989-10-26       Impact factor: 49.962

3.  A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase.

Authors:  M W Harding; A Galat; D E Uehling; S L Schreiber
Journal:  Nature       Date:  1989-10-26       Impact factor: 49.962

4.  FK 506 for liver, kidney, and pancreas transplantation.

Authors:  T E Starzl; S Todo; J Fung; A J Demetris; R Venkataramman; A Jain
Journal:  Lancet       Date:  1989-10-28       Impact factor: 79.321

5.  The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression.

Authors:  M A Nalesnik; R Jaffe; T E Starzl; A J Demetris; K Porter; J A Burnham; L Makowka; M Ho; J Locker
Journal:  Am J Pathol       Date:  1988-10       Impact factor: 4.307

6.  Cancers following cyclosporine therapy.

Authors:  I Penn
Journal:  Transplantation       Date:  1987-01       Impact factor: 4.939

7.  Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients.

Authors:  G Frizzera; D W Hanto; K J Gajl-Peczalska; J Rosai; R W McKenna; R K Sibley; K P Holahan; L L Lindquist
Journal:  Cancer Res       Date:  1981-11       Impact factor: 12.701
  7 in total
  8 in total

Review 1.  The role of EBV in post-transplant malignancies: a review.

Authors:  P Hopwood; D H Crawford
Journal:  J Clin Pathol       Date:  2000-04       Impact factor: 3.411

Review 2.  Lymphoproliferative disease in organ transplant recipients.

Authors:  M A Nalesnik
Journal:  Springer Semin Immunopathol       Date:  1991

3.  Posttransplant lymphoproliferative disorders occurring under primary FK 506 immunosuppression.

Authors:  J Reyes; A Tzakis; M Green; B Nour; M Nalesnik; D Van Thiel; M Martin; M K Breinig; J J Fung; M Cooper
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

4.  Long-term results of pediatric liver transplantation in a combined pediatric and adult transplant program.

Authors:  Paul R Atkison; B Catherine Ross; Sandy Williams; John Howard; John Sommerauer; Douglas Quan; William Wall
Journal:  CMAJ       Date:  2002-06-25       Impact factor: 8.262

Review 5.  Clinical and pathological features of post-transplant lymphoproliferative disorders (PTLD).

Authors:  M A Nalesnik
Journal:  Springer Semin Immunopathol       Date:  1998

Review 6.  Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation.

Authors:  D H Peters; A Fitton; G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

7.  Post-transplant lymphoproliferative disorders.

Authors:  K J Lewin
Journal:  Pathol Oncol Res       Date:  1997-09       Impact factor: 3.201

Review 8.  The antiviral prophylaxis of post-transplant lymphoproliferative disorder.

Authors:  C L Davis
Journal:  Springer Semin Immunopathol       Date:  1998
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.